This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 7
  • /
  • NPMA (China) conditionally approves Azvudine first...

NPMA (China) conditionally approves Azvudine first oral antiviral made in China to treat COVID 19

Read time: 1 mins
Published:27th Jul 2022

China’s drug regulator NPMA has granted conditional approval for an HIV drug to be used to treat COVID-19. The drug, Azvudine is developed by Chinese drugmaker Genuine Biotech and is the first oral antiviral for the disease made in China

Genuine Biotech said that 40% of people with COVID-19 who were given Azvudine for a week in a phase III clinical trial showed “improved clinical symptoms”, compared with 11% of those given a placebo. However, detailed data from the trial, including whether the treatment reduced the risk of hospitalization or death, have not been released.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.